ASH23leukemia
The Beat AML study assigns newly diagnosed patients to a biomarker specific treatment.
The goal of PedAL is to establish a data-driven developmental therapeutics program.
Dr. Osman discussed menin inhibitors for leukemia, and axatilimab treatment for graft-versus-host disease.
Advertisement
Mayo Clinic researchers released the data on relapsed or refractory patients with AML who were a median age of 65 years.
The trial's treatment regimen included single-agent dasatinib for the first three months, followed by venetoclax.
Investigators reviewed cladribine in combination with low dose cytarabine (LDAC) and venetoclax.
Advertisement
There was previously a gap in evidence when it came to how the drug works after treatment with covalent BTK inhibitors.
Dr. Xia Jiang and colleagues collected AML cell lines to test the efficacy of venetoclax with NL-101.
Researchers found that the proportion of cells in each CLL cluster was vastly different at relapse than it was at baseline.
Patients with CLL who eventually progress on BTK inhibitors highlights the need for new treatments.
The study tested the combination therapy in a patient-derived xenograft (PDX) model of NPM1-mutated AML.
Researchers identified which co-occurring mutations had the strongest significance and what the high incidence could mean.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.